We are thrilled to announce the finalists for BioBuzz’s 2023 Annual Awards for the BioHealth Capital Region (Maryland, Washington, DC, Virginia).
And the Finalists Are… Meet Your BioHealth Capital Region 2023 Annual Awards Finalists
Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors
Stanley Frankel, M.D., FACP Appointed as Interim Chief Medical Officer and Scientific Advisory Board Membe
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 7, 2023 Funding, Awards and Collaborations Horizon Therapeutics Named to [….]
Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR)
Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR) GERMANTOWN, Md., April 5, 2023 /PRNewswire/ — Deka Biosciences (“Deka”), a clinical-stage biotechnology company focused on developing novel cytokine [….]
Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application
Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application GERMANTOWN, Md., Jan. 30, 2023 /PRNewswire/ — Deka Biosciences (“Deka”), a biotech company focused on developing novel cytokine therapies to [….]
Deka Biosciences Continues Hitting Milestones, Builds Remarkable Momentum in Less Than a Year
Launched in 2019, Deka is the first cytokine-based biotech company to call the BioHealth Capital Region home. In less than a year, Deka has tripled in size and has consistently hit milestones that have expanded its capabilities, fostered growth, and advanced its promising pipeline. The company’s recent string of successes have been underpinned by innovative science propelled by top-notch scientists.
Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations
Deka Biosciences (“Deka”), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser, MD, PhD, MSc, MBA as Chief Medical Officer (CMO) and Deb Kientop, MBA as Vice President, Clinical Operations.
Deka BioSciences Breaks Ground on New Facility
Deka BioSciences announced today that it is breaking ground on a 14,000 square foot office and lab which will house a state of the art Research and Development, Process Development, and Manufacturing facility to further develop their novel cytokine therapies.
This will be the first facility to house a dual targeted cytokine development lab in the DC/Maryland/Virginia region and the only company in the US developing a therapeutic of its kind. The new headquarters will be located at 20380 Seneca Meadows Parkway in Germantown, Maryland and Deka anticipates the move to be completed in the first quarter of 2023.
Deka Biosciences Raises USD 20 Million in Series A Financing
Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD 20 Million Series A financing with a syndicate of life science investors led by Leaps by Bayer, the impact investment arm of Bayer AG, and new investor Lumira Ventures. Additional investors include O-Bio (Echo Investment Capital), Viva BioInnovator, and Alexandria Venture Investments.
In Conversation: John Mumm, Chief Executive Officer, Deka BioSciences
John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.